论文部分内容阅读
目的评价卡维地洛对重度心力衰竭患者的近期疗效及安全性。方法选择心功能Ⅳ级患者68例,随机分为卡维地洛组(C组)34例和美托洛尔组(M组)34例,治疗前和治疗结束时评价心功能分级,用超声心动图(UCG)测量左室射血分数(LVEF)。结果两组治疗后心功能均明显改善,射血分数增加,C组心功能的改善幅度大于M组(P<0.05)。结论重度心力衰竭患者应用卡维地洛治疗可明显改善心功能,近期疗效优于美托洛尔。
Objective To evaluate the short-term efficacy and safety of carvedilol in patients with severe heart failure. Methods Sixty-eight patients with grade Ⅳ cardiac function were selected and randomly divided into 34 cases in the carvedilol group (C group) and 34 cases in the metoprolol group (M group). The heart function was evaluated before and at the end of the treatment. Echocardiography (UCG) Measurement of left ventricular ejection fraction (LVEF). Results After treatment, the cardiac function of both groups improved significantly and the ejection fraction increased. The improvement of cardiac function in group C was more than that in group M (P <0.05). Conclusion Carvedilol treatment in patients with severe heart failure can significantly improve cardiac function, the recent efficacy is superior to metoprolol.